文献速递冠心病

心肌梗死后超过1年使用β受体阻滞剂与心血管结局的关联

Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes.
PubMed 文献 · Heart · 2023-07-12

倾向评分加权后,使用β受体阻滞剂与未使用者的主要复合终点风险无差异(HR 0.99;95%CI 0.93至1.04)。

要点

  • 无心力衰竭或左室收缩功能障碍的心梗后患者,超过1年使用β受体阻滞剂未改善心血管结局。
  • 倾向评分加权后主要复合终点风险无显著差异(HR 0.99;95%CI 0.93至1.04)。
  • 该结果不支持对无上述合并症的心梗后患者常规长期使用β受体阻滞剂超过1年。

核心结论

  • 瑞典全国队列研究提示,无心力衰竭或左室收缩功能障碍的心肌梗死后患者,超过1年使用β受体阻滞剂与心血管结局改善无关。

研究设计与样本

  • 排除截至索引日期存在心力衰竭或左室收缩功能障碍的患者,按β受体阻滞剂治疗分为两组。
  • 采用Cox和Fine-Grey回归模型,并进行逆倾向评分加权及多变量校正。

主要发现

  • 意向治疗分析中,未校正主要终点事件率在使用者与未使用者分别为3.8与4.9事件/100人年(HR 0.76;95%CI 0.73至1.04)。
  • 逆倾向评分加权和多变量校正后,主要复合终点风险无差异(HR 0.99;95%CI 0.93至1.04)。
  • 随访中删失β受体阻滞剂停药或换药后,结果相似。

临床怎么用

  • 对于无心力衰竭或左室收缩功能障碍的心肌梗死后患者,超过1年常规使用β受体阻滞剂可能不带来额外心血管获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Beta-blockers (BB) are an established treatment following myocardial infarction (MI). However, there is uncertainty as to whether BB beyond the first year of MI have a role in patients without heart failure or left ventricular systolic dysfunction (LVSD). METHODS: A nationwide cohort study was conducted including 43 618 patients with MI between 2005 and 2016 in the Swedish register for coronary heart disease. Follow-up started 1 year after hospitalisation (index date). Patients with heart failure or LVSD up until the index date were excluded. Patients were allocated into two groups according to BB treatment. Primary outcome was a composite of all-cause mortality, MI, unscheduled revascularisation and hospitalisation for heart failure. Outcomes were analysed using Cox and Fine-Grey regression models after inverse propensity score weighting. RESULTS: Overall, 34 253 (78.5%) patients received BB and 9365 (21.5%) did not at the index date 1 year following MI. The median age was 64 years and 25.5% were female. In the intention-to-treat analysis, the unadjusted rate of primary outcome was lower among patients who received versus not received BB (3.8 vs 4.9 events/100 person-years) (HR 0.76; 95% CI 0.73 to 1.04). Following inverse propensity score weighting and multivariable adjustment, the risk of the primary outcome was not different according to BB treatment (HR 0.99; 95% CI 0.93 to 1.04). Similar findings were observed when censoring for BB discontinuation or treatment switch during follow-up. CONCLUSION: Evidence from this nationwide cohort study suggests that BB treatment beyond 1 year of MI for patients without heart failure or LVSD was not associated with improved cardiovascular outcomes.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Ishak, Aktaa, Lindhagen, et al. Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes. Heart. 2023. PMID: 37130746. doi:10.1136/heartjnl-2022-322115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。